Home » Life Science & Biotech

Life Science & Biotech

Articles

Lilly reorganization to cut 5,500 positions over 2 years

Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.

Read More

INpact Medical Device Network matches start-ups with service providers

Industry groups in the life sciences, medical and information technology realms have helped lure companies to the region
and foster upstarts. Funding is almost always an issue, but it’s not the only barrier. Getting medical
devices to market often requires product design, development and marketing resources that aren’t
always apparent to upstarts.

Read More

Tenants trickling in to Purdue’s technology center

For a city feverishly growing its technology and life sciences sectors, it seemed a bit anticlimactic last January when
Purdue University dedicated its new technology center with only one tenant. But the lone tenant in the $12.8
million complex, FlamencoNets, a high-tech telecommunications firm, is about to get some company.

Read More

Dow Chemical seems poised to keep AgroSciences

Midland, Mich.-based Dow Chemical Co. is still considering divesting Indianapolis subsidiary Dow AgroSciences LLC. But
chances that the chemical manufacturing giant will sell its local agricultural chemical and biotech unit appear to have decreased.

Read More

Is Indiana coming out of venture capital swoon?

Carmel-based Dormir LLC’s announcement July 29 of $12 million in venture financing was the second local life sciences
deal announced in July. It could suggest a turnaround from a woeful second-quarter performance, when Indiana life
sciences firms announced zero venture capital deals.

Read More

Lilly’s Effient launch just one of its many challenges

Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.

Read More

Dow Agro sale still possible, but less likely

Midland, Mich.-based Dow Chemical Co. is still considering divesting Indianapolis subsidiary Dow AgroSciences LLC. But chances
that the chemical manufacturing giant will sell its local agricultural chemical and biotech unit have decreased.

Read More

Dow AgroSciences names new CEO

Indianapolis-based Dow AgroSciences LLC will have a new CEO after its parent organization moves Jerome Peribere into a new
position, the company announced today. Antonio Galindez, 54, vice president of Dow AgroSciences’ crops business, will step
into the top job.

Read More

Dow AgroSciences names new CEO

Indianapolis-based Dow AgroSciences LLC will have a new CEO after its parent organization moves Jerome Peribere into a new
position, the company announced today.

Read More

Dow Agrosciences introduces genetically modified corn seed

Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.

Read More